Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS

Conclusions The majority of patients who discontinued DMF due to lymphopenia experienced ALC reconstitution within 2–4 months following DMF discontinuation. This may help guide clinicians in managing patients who develop lymphopenia during DMF treatment. Prolonged lymphopenia on DMF treatment is associated with slow lymphocyte recovery after DMF discontinuation.

http://cp.neurology.org/cgi/content/short/10/6/510?rss=1

Source: Neurology Clinical Practice - December 7, 2020 Category: Neurology Authors: Chan, A., Rose, J., Alvarez, E., Bar-Or, A., Butzkueven, H., Fox, R. J., Gold, R., Gudesblatt, M., Haartsen, J., Spelman, T., Wright, K., Ferraro, D., Sola, P., Hodgkinson, S., Kalincik, T., Lechner-Scott, J., McGuigan, C., Spach, K., Chen, C., Fam, S., W Tags: All Clinical trials, Multiple sclerosis Research Source Type: research

More News: Brain | Clinical Trials | Multiple Sclerosis | Neurology | Study